Policy Brief Issue 25: South Korea’s Experience of Reimbursing High-Cost Medicines

Home > News > Publications > Documents > Policy Brief > Policy Brief Issue 25: South Korea’s Experience of Reimbursing High-Cost Medicines

Download Download 203

Views 964

Details

Cost-effectiveness and availability of alternative treatment options play a crucial role in the listing of new medicines in South Korea. However, high-cost medicines with no alternative treatment options, particularly those for treating cancer and rare diseases, were not reimbursed under the traditional route.

How the government of South Korea addresses this issue? Learn more from this policy brief.

Related Projects

Development of policy options to support reimbursement decision on high-cost health interventions in Thailand’s public healthcare system

Top

Policy Brief Issue 25: South Korea’s Experience of Reimbursing High-Cost Medicines

Details

Related Projects

Menu

Follow Us On

Subscribe to our mailing list

HITAP เข้าสู่ระบบ

Policy Brief Issue 25: South Korea’s Experience of Reimbursing High-Cost Medicines

Details

Related Projects

Menu

Follow Us On

Subscribe to our mailing list

Subscribe to our mailing list